A limitation for the use of PSMA radiopharmaceuticals in primary PCa is the relatively high binding of [177Lu]Lu-PSMA-617 to BPH samples and normal tissue surrounding primary PCa with ISUP grade 2 and 3, as observed in our study. This evidence concerns the gene FOLH1 and benign prostatic hyperplasia.